Oppenheimer Has Positive Stance On Momenta Pharmaceuticals

According to Oppenheimer, Momenta Pharmaceuticals MNTA holds a positive stance. Oppenheimer said that on 7/11, the U.S. District Court will begin hearings regarding inequitable conduct claims in the TEVA vs. MYL/Sandoz Copaxone patent litigation. “However, it is possible for the Copaxone patents to be defeated on inequitable conduct grounds, and therefore we have researched the background of important hearing witnesses. We continue to have a positive stance on MNTA, even assuming the company does not successfully defeat TEVA's Copaxone patents.” Momenta Pharmaceuticals closed on Friday at $20.92.